Therefore we first tried to verify the responsiveness of breast cancer cells to exogenous TGF-β by detecting the transcription of PAI-1, a target gene of TGF-β [30], after TGF-β treatment (100 pM for 2 h). The gene discussed is TGFB1; the disease is breast carcinoma.